The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG.

The main questions it aims to answer is:

1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG.
2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis.

Researchers will compare colchicine to none to see if colchicine works.

Participants will

1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG.
2. Clinical follow-up at Month 1, 6, and 12 after CABG.
3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.

Inclusion Criteria:

• Age≥18 years old，
• Any sex，
• Signed informed consent，
• Within 3 days after a successful isolated CABG

Exclusion Criteria:

• Allergy,
• Hematopoietic dysfunction,
• Moderate to severe hepatic dysfunction,
• Moderate to severe renal dysfunction.